H3K4me3
癌症研究
髓系白血病
神经母细胞瘤RAS病毒癌基因同源物
生物
白血病
组蛋白H3
下调和上调
髓样
组蛋白
基因表达
遗传学
基因
突变
发起人
克拉斯
作者
Shintaro Izumi,K Ohtani,Makoto Matsumoto,Seito Shibata,Bahityar Rahmutulla,Masaki Fukuyo,Mitsutaka Nishimoto,Hideo Miyagawa,Emiko Sakaida,Koutaro Yokote,Issay Kitabayashi,Kimi Araki,Atsushi Kaneda,Takayuki Hoshii
出处
期刊:Leukemia
[Springer Nature]
日期:2025-05-08
标识
DOI:10.1038/s41375-025-02638-y
摘要
Abstract Histone H3 lysine 4 trimethylation (H3K4me3) is abundant in mixed-lineage leukemia-rearranged (MLL-r) acute myeloid leukemia (AML) cells; however, the responsible enzymes and their roles remain unclear. This study aimed to identify the modifier responsible for high H3K4me3 modification in MLL-r leukemia and its downstream targets essential for the cell proliferation. Here, we performed a CRISPR-tiling screen against known H3K4 methylation modifiers in an MLL-r AML model. Disrupting the SETD1B catalytic SET domain caused depletion of FLT3-ITD or Nras G12D -expressing AML cells, and gene expression downregulation, particularly in the MYC pathway. SETD1B SET domain loss results in a significant decrease in H3K4me3 breadth. Exogenous MYC expression or disrupting H3K4 demethylase KDM5C significantly restored growth defects in SETD1B SET domain-mutant cells. These data indicated that SETD1B was required for H3K4me3 breadth and MYC expression. Thus, a thorough understanding of SETD1B-mediated H3K4me3 breadth is critical for developing markers and therapies for MYC-dependent leukemia subtypes.
科研通智能强力驱动
Strongly Powered by AbleSci AI